Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ciclesonide in Children With Perennial Allergic Rhinitis
NCT00163514Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- May 2004
- Primary completion
- Jul 2005
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of ciclesonide in perennial allergic rhinitis (PAR) (4 arms), sponsored by AstraZeneca. Primary endpoint: Total Nasal Symptom Score. Started May 2004; status: completed.
02
Drugs
ciclesonide
03
Conditions
perennial allergic rhinitis (PAR)
Beyond the preview
Go deeper on NCT00163514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00163514.